Zaloguj się

Gotowe bibliografie tematyczne / Antibody-toxin conjugates

Spis treści

Artykuły w czasopismach
Rozprawy doktorskie
Książki
Części książek
Streszczenia konferencji

Gotowa bibliografia na temat „Antibody-toxin conjugates”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 26 stycznia 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Antibody-toxin conjugates”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Antibody-toxin conjugates"

1

Esteva, Francisco J., Kathy D. Miller, and Beverly A. Teicher. "What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?" American Society of Clinical Oncology Educational Book, no. 35 (May 2015): e117-e125. http://dx.doi.org/10.14694/edbook_am.2015.35.e117.

Pełny tekst źródła

Streszczenie:

Antibody conjugates are a diverse class of therapeutics that consist of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody conjugates has been marked by hurdles identified and overcome. Early conjugates used mouse antibodies, drugs that either were not sufficiently potent, were immunogenic (proteins), or were too toxic, and linkers that were not suffi

Style APA, Harvard, Vancouver, ISO itp.

2

Ahmad, Ateeq, and Kevin Law. "Strategies for designing antibody-toxin conjugates." Trends in Biotechnology 6, no. 10 (October 1988): 246–51. http://dx.doi.org/10.1016/0167-7799(88)90056-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Govindan, Serengulam V., and David M. Goldenberg. "New Antibody Conjugates in Cancer Therapy." Scientific World JOURNAL 10 (2010): 2070–89. http://dx.doi.org/10.1100/tsw.2010.191.

Pełny tekst źródła

Streszczenie:

Targeting of radiation, drugs, and protein toxins to cancers selectively with monoclonal antibodies (MAbs) has been a topic of considerable interest and an area of continued development. Radioimmunotherapy (RAIT) of lymphoma using directly labeled MAbs is of current interest after approval of two radiolabeled anti-CD20 MAbs, as illustrated with the near 100% overall response rate obtained in a recent clinical trial using an investigational radiolabeled anti-CD22 MAb,90Y-epratuzumab. The advantage of pretargeted RAIT over directly labeled MAbs is continuing to be validated in preclinical models

Style APA, Harvard, Vancouver, ISO itp.

4

Liang, X. P., M. E. Lamm, and J. G. Nedrud. "Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus." Journal of Immunology 141, no. 5 (September 1, 1988): 1495–501. http://dx.doi.org/10.4049/jimmunol.141.5.1495.

Pełny tekst źródła

Streszczenie:

Abstract Successful oral immunization to prevent infectious diseases in the gastrointestinal tract as well as distant mucosal tissues may depend on the effectiveness of an Ag to induce gut immune responses. We and others have previously reported that cholera toxin possesses strong adjuvant effects on the gut immune response to co-administered Ag. To explore further adjuvant effects of cholera toxin, the holotoxin or its B subunit was chemically cross-linked to Sendai virus. The resulting conjugates, which were not infectious, were evaluated for their capacity to induce gut immune responses aga

Style APA, Harvard, Vancouver, ISO itp.

5

Panjideh, Hossein, Nicole Niesler, Alexander Weng, and Hendrik Fuchs. "Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861." Toxins 14, no. 7 (July 13, 2022): 478. http://dx.doi.org/10.3390/toxins14070478.

Pełny tekst źródła

Streszczenie:

Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. The plant glycoside SO1861 was previously reported to enhance the endolysosomal escape of antibody-toxin conjugates in non-hematopoietic cells, thus increasing their cytotoxicity manifold. Here we tested this technology for the first time in a lymphoma in vivo model. First, the therapeutic CD20 antibody obinutuzumab was chemically conjugated to the ribosome-inactivating protein dianthin. The

Style APA, Harvard, Vancouver, ISO itp.

6

Faria, Morse, Marlking Peay, Brandon Lam, Eric Ma, Moucun Yuan, Michael Waldron, William Mylott, Meina Liang, and Anton Rosenbaum. "Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2." Antibodies 8, no. 1 (January 11, 2019): 11. http://dx.doi.org/10.3390/antib8010011.

Pełny tekst źródła

Streszczenie:

Bioanalysis of complex biotherapeutics, such as antibody-drug conjugates (ADCs), is challenging and requires multiple assays to describe their pharmacokinetic (PK) profiles. To enable exposure-safety and exposure-efficacy analyses, as well as to understand the metabolism of ADC therapeutics, three bioanalytical methods are typically employed: Total Antibody, Antibody Conjugated Toxin or Total ADC and Unconjugated Toxin. MEDI4276 is an ADC comprised of biparatopic humanized antibody attached via a protease-cleavable peptide-based maleimidocaproyl linker to a tubulysin toxin (AZ13599185) with an

Style APA, Harvard, Vancouver, ISO itp.

7

Yu, Rui, Junjie Xu, Tao Hu, and Wei Chen. "The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity." Mediators of Inflammation 2020 (July 4, 2020): 1–11. http://dx.doi.org/10.1155/2020/9596129.

Pełny tekst źródła

Streszczenie:

The encapsulated bacteria, as Streptococcus pneumonia, Haemophilus influenzae type b, and Neisseria meningitidis, cause serious morbidity and mortality worldwide. The capsular polysaccharide (PS), which could elicit a weak T cell-independent immune response, is a vital virulence determinant. One of the strategies to improve the PS-specific immunogenicity is to conjugate PS with a nontoxic carrier protein. Tetanus toxoid (TT) and CRM197 are the typical carrier proteins for the PS conjugate vaccines. TT is the inactivated tetanus toxin manipulated with formaldehyde, which suffers from the pollut

Style APA, Harvard, Vancouver, ISO itp.

8

Marsh, J. W., and D. M. Neville. "A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins." Journal of Immunology 140, no. 10 (May 15, 1988): 3674–78. http://dx.doi.org/10.4049/jimmunol.140.10.3674.

Pełny tekst źródła

Streszczenie:

Abstract Immunotoxins, constructed by chemically cross-linking an antibody and protein toxin, do not possess the high efficacy of the native toxin. Decreases in toxicity are due in part to the steric constraints imposed on the two macromolecules, which result in both decreased antibody binding and toxin function. In examining the structural features that influence efficacy in holotoxin-antibody conjugates, it was found that the incorporation of a 29-residue polypeptide, derived from the insulin B chain between the antibody and ricin moiety, resulted in an increase in both potency and efficacy.

Style APA, Harvard, Vancouver, ISO itp.

9

Govindan, Serengulam V., Gary L. Griffiths, Hans J. Hansen, Ivan D. Horak, and David M. Goldenberg. "Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies." Technology in Cancer Research & Treatment 4, no. 4 (August 2005): 375–91. http://dx.doi.org/10.1177/153303460500400406.

Pełny tekst źródła

Streszczenie:

Radioimmunotherapy and antibody-directed chemotherapy have emerged as cancer treatment modalities with the regulatory approval of products for non-Hodgkin's lymphoma and acute myeloid leukemia. Antibody-toxin therapy is likewise on the verge of clinical fruition. Accumulating evidence suggests that radioimmunotherapy may have the best impact in minimal-disease and adjuvant settings, especially with radioresistant solid tumors. For the latter, ongoing efforts in ‘pretargeting’ to increase deliverable tumor radiation dose, combination therapies, and locoregional applications are also of importan

Style APA, Harvard, Vancouver, ISO itp.

10

Lefeber, Dirk J., Barry Benaissa-Trouw, Johannes F. G. Vliegenthart, Johannis P. Kamerling, Wouter T. M. Jansen, Kees Kraaijeveld, and Harm Snippe. "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3." Infection and Immunity 71, no. 12 (December 2003): 6915–20. http://dx.doi.org/10.1128/iai.71.12.6915-6920.2003.

Pełny tekst źródła

Streszczenie:

ABSTRACT Oligosaccharide (OS)-protein conjugates are promising candidate vaccinesagainst encapsulated bacteria, such as Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae. Although the effects of several variables such as OS chain length and protein carrier have been studied, little is known about the influence of adjuvants on the immunogenicity of OS-protein conjugates. In this study, a minimal protective trisaccharide epitope of Streptococcus pneumoniae type 3 conjugated to the cross-reacting material of diphtheria toxin was used for immunization of BALB/c mice in t

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Rozprawy doktorskie na temat "Antibody-toxin conjugates"

1

Ng, Wai-yun Louisa. "Production of variants of mitogillin with reduced IgE binding activity." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972093.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Ng, Wai-yun Louisa, and 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Kwok, Hon Hung. "Immunolesioning in the rat brain." HKBU Institutional Repository, 1999. http://repository.hkbu.edu.hk/etd_ra/234.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

"Construction of a Recombinant Immunotoxin." University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/2100/270.

Pełny tekst źródła

Streszczenie:

In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds to human free kappa light chains and recognises a specif

Style APA, Harvard, Vancouver, ISO itp.

5

"Construction of a recombinant immunotoxin." Thesis, University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/10453/20069.

Pełny tekst źródła

Streszczenie:

University of Technology, Sydney. Faculty of Science.<br>In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds

Style APA, Harvard, Vancouver, ISO itp.

6

XU, HAO-JI, and 徐鎬基. "Studies on immunotoxin-monoclonal antibody 9.5D-abrin toxin a chain conjugates-against the grith of human cervical cancer cell lines." Thesis, 1991. http://ndltd.ncl.edu.tw/handle/82906099079103529855.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "Antibody-toxin conjugates"

1

Mark, Chamow Steven, and Ashkenazi Avi, eds. Antibody fusion proteins. New York: Wiley-Liss, 1999.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

E, Frankel Arthur, ed. Immunotoxins. Boston: Kluwer Academic Publishers, 1988.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Phan, Văn Chi. Trichobakin và Immunotoxin tái tổ hợp. Hà Nội: Nhà xuất bản Khoa học tự nhiên và công nghệ, 2008.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Ramakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

1960-, Tyle Praveen, and Ram Bhanu P. 1951-, eds. Targeted therapeutic systems. New York: Dekker, 1990.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

1947-, Wiley Ronald G., and Lappi Douglas A, eds. Molecular neurosurgery with targeted toxins. Totowa, N.J: Humana Press, 2005.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

A, Lappi Douglas, ed. Suicide transport and immunolesioning. Austin: R.G. Landes, 1994.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Frankel, Arthur E. Immunotoxins. Springer, 2012.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Immunotoxin Methods and Protocols. Humana Press, 2001.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Frankel, A. Clinical Applications of Immunotoxins (Current Topics in Microbiology and Immunology). Springer-Verlag Telos, 1998.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Części książek na temat "Antibody-toxin conjugates"

1

Cumber, Alan J., and Edward J. Wawrzynczak. "Preparation of Cytotoxic Antibody—Toxin Conjugates." In Immunochemical Protocols, 135–44. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_13.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Pietersz, Geoffrey, and Ian McKenzie. "Immunotherapy for Cancer—Toxin-Antibody Conjugates." In Toxins and Targets, 65–74. London: Routledge, 2022. http://dx.doi.org/10.4324/9781315076911-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Neville, David M. "Monoclonal Antibody Mediated Drug Delivery and Antibody Toxin Conjugates." In Directed Drug Delivery, 211–30. Totowa, NJ: Humana Press, 1985. http://dx.doi.org/10.1007/978-1-4612-5186-6_12.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Blakey, David C., Edward J. Wawrzynczak, Philip M. Wallace, and Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 1 of 2)." In Monoclonal Antibody Therapy, 50–70. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318800.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Blakey, David C., Edward J. Wawrzynczak, Philip M. Wallace, and Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 2 of 2)." In Monoclonal Antibody Therapy, 71–90. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318801.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Wawrzynczak, Edward J., and Alan J. Cumber. "Immunoaffinity Purification and Quantification of Antibody—Toxin Conjugates." In Immunochemical Protocols, 145–53. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_14.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Ohtani, Katsumi, and Yoshio Ueno. "Selective Antitumor Activity of T-2 Toxin-Antibody Conjugates." In Microbial Toxins in Foods and Feeds, 403–9. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0663-4_38.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Colombatti, M., M. Bisconti, P. Lorenzi, G. Stevanoni, B. Dipasquale, M. Gerosa, and G. Tridente. "Human Glioma Cell Lines: Tumour Associated Antigens Distribution and Sensitivity to Antibody-Toxin or Ligand-Toxin Conjugates. A Preliminary Report." In Proceedings of the 8th European Congress of Neurosurgery, Barcelona, September 6–11, 1987, 121–25. Vienna: Springer Vienna, 1988. http://dx.doi.org/10.1007/978-3-7091-8978-8_26.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Oldham, Robert K. "Antibody-Drug and Antibody-Toxin Conjugates." In Immunity to Cancer, 575–85. Elsevier, 1985. http://dx.doi.org/10.1016/b978-0-12-586270-7.50053-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

"Antibody Toxin Fusions or Conjugates." In Encyclopedia of Cancer, 268. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-46875-3_100201.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Antibody-toxin conjugates"

1

Terrett, Jonathan A., Rachel Dusek, Dee Aud, Rahel Awdew, Sudha Swaminathan, San Lin Lou, Michael Trang, et al. "Abstract 661: Proteomics and selecting the right combination of target and toxin for antibody-drug-conjugate (ADC) development." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-661.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Rickles, Richard J., Thomas P. Giordano, Shakira F. Cotard, Jill M. Grenier, Angela Romanelli, and Ti Cai. "Abstract 4765: Drug synergies observed for antibody and toxin components of SAR3419 ADC contribute to overall conjugate efficacy and can be combination drug or tumor cell line dependent." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4765.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!